Bibliography
- Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168-81
- McDonald PC, Winum JY, Supuran CT, et al. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 2012;3:84-7
- Gieling RG, Williams KJ. Carbonic anhydrase IX as a target for metastatic disease. Bioorg Med Chem 2012; In press
- Poulsen SA. Carbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007-2009. Expert Opin Ther Patents 2010;20:795-806
- Aggarwal M, McKenna R. Update on carbonic anhydrase inhibitors: a patent review (2008-2011). Expert Opin Ther Patents 2012;22:903-15
- Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759-72
- Winum JY, Rami M, Scozzafava A, et al. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med Res Rev 2008;28:445-63
- Casey JR, Morgan PE, Vullo D, et al. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J Med Chem 2004;47:2337-47
- Bayer HealthCare AG. et al. CA IX specific inhibitors. WO2004048544; 2004
- Cecchi A, Hulikova A, Pastorek J, et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 2005;48:4834-41
- Supuran CT, Scozzafava A. Fluorescent sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as therapeutic and diagnostic agents. WO2006137092; 2006
- Winum J-Y. Carbonic anhydrase IX inhibitors: fluorescent sulfonamides as therapeutic and diagnostic agents. Expert Opin Ther Patents 2007;17:1393-6
- Siemens Medical Solutions USA, Inc. The development of molecular imaging probes for carbonic anhydrase-IX using click chemistry. WO124703; 2008
- Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase IX. WO089383; 2009
- Winum J-Y, Poulsen SA, Supuran CT. Therapeutic applications of glycosidic carbonic anhydrase inhibitors. Med Res Rev 2009;29:419-35
- Winum J-Y, Colinas PA, Supuran CT. Glycosidic carbonic anhydrase IX inhibitors: a sweet approach against cancer. Bioorg Med Chem 2012; In press
- Touisni N, Maresca A, McDonald PC, et al. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J Med Chem 2011;54:8271-7
- Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364-76
- Metasignal Therapeutics, Inc. et al. Carbonic anhydrase inhibitors with antimetastatic activity. WO2012070024; 2012
- Zatovicova M, Jelenska L, Hulikova A, et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des 2010;16:3255-63
- Bayer AG. et al. MN/CAIX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use. WO 03100029; 2003
- Carney WP. Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Expert Rev Mol Diagn 2007;7:309-19
- Lam JS, Pantuck AJ, Belldegrun AS, et al. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep 2005;7:109-15
- Stillebroer AB, Mulders PF, Boerman OC, et al. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010;58:75-83
- Wilex AG announces results of Phase III ARISER study with RENCAREX® in clear cell renal cell carcinoma. 2012. Available from: http://www.wilex.de/press-investors/announcements/press-releases/20121016-2/
- Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2011;29:121-6
- Ullrich S, Warnaar OS, Wilex AG. Co-administration of CG250 and IL-2 or INF-alpha for treating cancer such as renal cell carcinomas. WO2004002526; 2004
- Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007;8:304-10
- ClinicalTrials.gov A service of the U.S. National Institutes of Health. Available from: http://clinicaltrials.gov/ct2/results?term=cG250